March 30, 2020

Clinical Reports

  • Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
    During the first 3 weeks of the Covid-19 outbreak in the Seattle area, the most common reasons for admission to the ICU were hypoxemic respiratory failure leading to mechanical ventilation, hypotension requiring vasopressor treatment, or both. Mortality among these critically ill patients was high.

  • COVID-19: consider cytokine storm syndromes and immunosuppression.
    Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome. Authors recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality.

Antiviral Therapeutics and Vaccines

  • Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study
    In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin authors noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year- old patient still in ICU. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. These results allowed patients to be rapidly discharged from contagious wards with a mean length of stay of five days. A modified National Early Warning Score [NEWS] was calculated and added age and temperature to characterize the severity of Covid-19 patients in the study. The NEWS score is one measure to facilitate cross study comparisons of future studies that are needed to replicate this exploratory study with adequate control groups.

  • FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro
    Authors present data on 20 FDA approved drugs tested for antiviral activity against SARS-CoV-2 previously found to inhibit SARS-CoV and MERS-CoV. Seventeen of these also inhibit SARS-CoV-2 at a range of IC50 values at non-cytotoxic concentrations including hydroxychloroquine sulfate and chloroquine phosphate.

  • Landscape of SARS-CoV-2 vaccine candidates
    A pdf from WHO listing vaccines in clinical (2) and pre-clinical (48) evaluation.


Basic Virology

Terminal Curiosities

Situation Dashboards


World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information


World Health Organization (WHO)


Centers for Disease Control, US


International Society for Infectious Diseases


This Week in Virology (TWIV)

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.

Scroll to Top